Search - tctmd.com

Displaying 661 - 680 of 1896

Sort: Relevancy | Date

CT Perfusion Imaging for In-Stent Restenosis Shows Promise

News Daily News

CT Perfusion Imaging for In-Stent Restenosis Shows Promise

Yael L. Maxwell

August 15, 2019

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

August 07, 2019

Nighttime, 24-Hour BP Readings Have Strongest Link to Poor Outcomes

News Daily News

Nighttime, 24-Hour BP Readings Have Strongest Link to Poor Outcomes

August 06, 2019

DOACs Good for Secondary Prevention in Older A-fib Patients, Real-world Numbers Affirm

News Daily News

DOACs Good for Secondary Prevention in Older A-fib Patients, Real-world Numbers Affirm

July 23, 2019

Machine Learning Helps Predict In-Hospital Mortality Post-TAVR, but Skepticism Abounds

News Daily News

Machine Learning Helps Predict In-Hospital Mortality Post-TAVR, but Skepticism Abounds

July 19, 2019

Large, US Study Supports Single High-Sensitivity Troponin I Test for Suspected Acute MI

News Daily News

Large, US Study Supports Single High-Sensitivity Troponin I Test for Suspected Acute MI

July 16, 2019

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

News Daily News

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Marcus A. Banks

July 12, 2019

Multiple Passes During Stroke Thrombectomy Ups Risk of Blood-Brain Barrier Disruption

News Daily News

Multiple Passes During Stroke Thrombectomy Ups Risk of Blood-Brain Barrier Disruption

Alison Palkhivala

July 05, 2019

Smoking More Strongly Linked to STEMI in Women Than in Men

News Daily News

Smoking More Strongly Linked to STEMI in Women Than in Men

Marcus A. Banks

June 27, 2019

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

June 26, 2019

News Industry News

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

June 26, 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

Potential Warning Signs Seen for NOAC Use After TAVR

News Daily News

Potential Warning Signs Seen for NOAC Use After TAVR

June 12, 2019

‘These Are Good Organs’: Drug Overdose Deaths Boost Transplants, With Few Downsides

News Daily News

‘These Are Good Organs’: Drug Overdose Deaths Boost Transplants, With Few Downsides

June 10, 2019

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

June 10, 2019

Endocarditis After TAVR: Real-world Data Speak to Its Rarity but Also the ‘Devastating’ Impact

News Conference News EuroPCR 2019

Endocarditis After TAVR: Real-world Data Speak to Its Rarity but Also the ‘Devastating’ Impact

June 07, 2019

Mortality Lower When STEMI Patients Sent to the ICU, but Why?

News Daily News

Mortality Lower When STEMI Patients Sent to the ICU, but Why?

June 06, 2019

Terumo’s Solopath Transfemoral System and Recollapsible Balloon Access System Recalled for Dislodging Issues

News Daily News

Terumo’s Solopath Transfemoral System and Recollapsible Balloon Access System Recalled for Dislodging Issues

May 30, 2019

OVER Trial: Long-term Mortality Similar After Endovascular and Open AAA Repair

News Daily News

OVER Trial: Long-term Mortality Similar After Endovascular and Open AAA Repair

May 30, 2019

Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis

News Conference News ESC Heart Failure 2019

Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis

May 26, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.